Journal Article Review Epublish 76 citations
PubMed: 36902329 DOI: 10.3390/ijms24054901
Psoriatic Arthritis: Pathogenesis and Targeted Therapies.
Int J Mol Sci 24(5)
Authors: Ana Belén Azuaga, Julio Ramírez, Juan D Cañete
Affiliations
- Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, 08036 Barcelona, Spain.
Abstract
Psoriatic arthritis (PsA), a heterogeneous chronic inflammatory immune-mediated disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis, and dactylitis), generally occurs in patients with psoriasis. PsA is also associated with uveitis and inflammatory bowel disease (Crohn's disease and ulcerative colitis). To capture these manifestations as well as the associated comorbidities, and to recognize their underlining common pathogenesis, the name of psoriatic disease was coined. The pathogenesis of PsA is complex and multifaceted, with an interplay of genetic predisposition, triggering environmental factors, and activation of the innate and adaptive immune system, although autoinflammation has also been implicated. Research has identified several immune-inflammatory pathways defined by cytokines (IL-23/IL-17, TNF), leading to the development of efficacious therapeutic targets. However, heterogeneous responses to these drugs occur in different patients and in the different tissues involved, resulting in a challenge to the global management of the disease. Therefore, more translational research is necessary in order to identify new targets and improve current disease outcomes. Hopefully, this may become a reality through the integration of different omics technologies that allow better understanding of the relevant cellular and molecular players of the different tissues and manifestations of the disease. In this narrative review, we aim to provide an updated overview of the pathophysiology, including the latest findings from multiomics studies, and to describe current targeted therapies.
MeSH
Cytokines, Arthritis, Psoriatic, Therapeutics, Biological Therapy, Tissues
Cited by
- Identifying Serum Metabolomic Markers Associated with Skin Disease Activity in Patients with Psoriatic Arthritis. Int J Mol Sci, 2023
- Psoriasis increases the risk of Sjögren's syndrome: evidence from a propensity score-matched cohort study and transcriptomic analysis. BMC Med, 2025
- A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases. Int J Mol Sci, 2025
- Exploring the causal relationship between inflammatory cytokines and immunoinflammatory dermatoses: a Mendelian randomization study. Front Med (Lausanne), 2024
- Psoriatic Arthritis Involving TMJ: A Review on Pathogenesis and Consideration on Eventual Gender Differences. Dent J (Basel), 2024
- From PsO to PsA: the role of T and Tregs in psoriatic disease, a systematic review of the literature. Front Med (Lausanne), 2024
- Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network. BioDrugs, 2025
- JAK Inhibitors in Psoriatic Disease. Clin Cosmet Investig Dermatol, 2023
- Trace Elements-Role in Joint Function and Impact on Joint Diseases. Int J Mol Sci, 2025
- Psoriasis and Seasonality: Exploring the Genetic and Epigenetic Interactions. Int J Mol Sci, 2024
- Navigating Psoriatic Arthritis: Treatment Pathways and Patient-Specific Strategies for Improved Outcomes. Drugs, 2025
- The Contribution of Macrophage Plasticity to Inflammatory Arthritis and Their Potential as Therapeutic Targets. Cells, 2024
- Shared Pathophysiology of Inflammatory Bowel Disease and Psoriasis: Unraveling the Connection. Cureus, 2024
- Difficult to Treat Psoriatic Arthritis: The Road So Far. Mediterr J Rheumatol, 2025
- Effects of Different Therapeutic Approaches on Redox Balance in Psoriatic Patients. Biomedicines, 2024
- Prevalence of psoriatic arthritis in Italy: insights from the multicentric MAPSI study. Front Med (Lausanne), 2025
- Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study. Arthritis Rheumatol, 2025
- Guselkumab Retention, Effectiveness, and Safety in Psoriasis: A 260-Week Real-World Multicenter Retrospective Study Exploring the Role of Concomitant PsA-IL PSO (Italian Landscape Psoriasis). Dermatol Ther (Heidelb), 2025
- Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany. Adv Ther, 2025
- Oxidative Imbalance in Psoriasis with an Emphasis on Psoriatic Arthritis: Therapeutic Antioxidant Targets. Molecules, 2024